Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO
· Real-Time Price · USD
6.86
0.30 (4.57%)
At close: May 01, 2025, 3:59 PM
6.80
-0.80%
After-hours: May 01, 2025, 06:12 PM EDT
4.57% (1D)
| Bid | 6.8 |
| Market Cap | 334.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.73M |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -4.42 |
| Forward PE | -65.55 |
| Analyst | Buy |
| Ask | 6.84 |
| Volume | 3,225,117 |
| Avg. Volume (20D) | 1,141,508 |
| Open | 6.54 |
| Previous Close | 6.56 |
| Day's Range | 6.38 - 7.04 |
| 52-Week Range | 3.84 - 7.32 |
| Beta | 1.70 |
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 19, 1980
Employees 136
Stock Exchange NASDAQ
Ticker Symbol ABEO
Analyst Forecast
According to 4 analyst ratings, the average rating for ABEO stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 177.17% from the latest price.
Stock ForecastsNext Earnings Release
Abeona Therapeutics Inc. is scheduled to release its earnings on May 14, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 days ago
+23.77%
Abeona Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
3 days ago
-0.93%
ABEO stock has given up its prior gain. Abeona Therapeutics shares were trading higher after the company announced FDA approval of ZEVASKYN for treating wounds in patients with recessive dystrophic epidermolysis bullosa.
